LEADER 04064nam  22006255  450 
001 9910369933103321
005 20200701041551.0
010   $a3-030-26439-4
024 7 $a10.1007/978-3-030-26439-0
035   $a(CKB)4100000009523019
035   $a(DE-He213)978-3-030-26439-0
035   $a(MiAaPQ)EBC5941798
035   $a(iGPub)SPNA0062691
035   $a(PPN)258851929
035   $a(EXLCZ)994100000009523019
100   $a20191011d2020      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aTumor Liquid Biopsies /$fedited by Florence Schaffner, Jean-Louis Merlin, Nikolas von Bubnoff
205   $a1st ed. 2020.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020.
215   $a1 online resource (VI, 368 p.) 
225 1 $aRecent Results in Cancer Research,$x0080-0015 ;$v215
311   $a3-030-26438-6 
320   $aIncludes bibliographical references.
327   $aCirculating Tumor Cells: Pathophysiology of Tumor Cell Release into the Circulation and characterization of CTC -- CTC enrichment technologies -- Genotyping of CTC :example Lung cancer -- CTC in Breast Cancer: a clinical approach -- Circulating Tumor DNA: Pathophysiology of ctDNA Release into the Circulation and its characterization -- Enrichment and Analysis of ctDNA -- ctDNA in Lung Cancer -- ctDNA in Breast Cancer -- ctDNA in Colorectal Cancer -- Dynamic Treatment Stratification using ctDNA -- Circulating Tumor RNA: Noncoding Tumor RNAs: Pathophysiology of Release and Techniques of Detection -- Circulating miRNAs as Biomarker in Cancer -- Plasma Subcompartments as Source for Tumor derived Biomarkers: Exosomes and Vesicles as Biomarker in Cancer -- Quantitative proteomic Analysis of Plasma in Cancer.
330   $aThis book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.
410  0$aRecent Results in Cancer Research,$x0080-0015 ;$v215
606   $aOncology
606   $aPathology
606   $aCancer$xResearch
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aPathology$3https://scigraph.springernature.com/ontologies/product-market-codes/H4800X
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aOncology.
615  0$aPathology.
615  0$aCancer$xResearch.
615 14$aOncology.
615 24$aPathology.
615 24$aCancer Research.
676   $a616.994
676   $a616.994075
702   $aSchaffner$b Florence$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aMerlin$b Jean-Louis$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $avon Bubnoff$b Nikolas$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910369933103321
996   $aTumor Liquid Biopsies$92047276
997   $aUNINA